

## August 2022

A short mid-quarter report to highlight some of last month's price concessions, in case they continue this month.

These are all shown by scrolling right in the adjacent Drug Tariff Updates worksheet.

There may not be much we can do about these as they are unpredictable and prices may reduce in subsequent months.

However, some significant cost-pressures are likely to arise if some of these concessions persist.

Largest percentage concession goes to aledronic 70mg tablets, which are a whopping 19 times the usual Tariff price (1283 vs 68p)

Next in descending order are temazepam tablets where 10 and 20mg are 15 and 14 times their usual prices respectively.

Other high volume lines with significant concessions include: rabeprazole 20mg tablets (over six and a half times Category M price), venlafaxine 75mg tablets (over five and a half times Category M price), tiroprium 20mg tablets (four and a half times), clarithromycin 500mg tablets (four times), duloxetine 30 and 60mg capsules (three times), fluoxetine 20mg capsules (over twice), solifenacin 5 and 10mg tablets (twice), prasugrel 10mg tablets (almost twice), sulphasalazine 500mg tablets (almost twice), risedronate 35mg tablets (almost twice) and ibandronic acid 50mg tablets (half as much again).

In total, there were 94 lines with price concessions last month, and at the time of writing (17th), 44 concessions have already been granted for this month.

For more information on price concessions, please see the PSNC briefing here: <https://psnc.org.uk/wp-content/uploads/2022/08/Price-concession-briefing-August-2022.pdf>

As always, Category M price changes are compared with last quarter while Category A changes are compared against last month.